SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Stressgen (VSE: SSB)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Heat Shock who wrote (175)12/4/2001 6:38:34 PM
From: Heat Shock  Read Replies (1) of 236
 
To all: I listened to the very long conference call and made a few hasty notes.

- upbeat mood. The analysts who asked questions said things like "excellent data" and "congratulations on the data" and "impressed with the data"

- the low dose of 100 mcg 3 times was the same as placebo, so the high dose of 500 mcg 3 times will be used in the trials from now on.

- for the first time there was a lot of talk about the percentage of "clearance" of disease- complete cure

- the complete remissions are time dependent

- the complete remissions are durable- no recurrence, or very little

- partnership. CEO Korpolinski said Stressgen was having "a number of discussions" and some new people were interested in genital warts. Later he said there were "a large number of potential partners" and a deal might be in the first half 2002.

- John Neefe said that HspE7 could easily be presented as a first line therapy, not an adjunct to surgery, although some doctors might use it that way

- numerous marketing strategies are being considered. One would have the therapy at a premium price for specialty use in difficult cases like internal warts, large external warts, and refractory cases.

- Korpolinski said the orphan drug status indication RRP could be the first to FDA approval and he even said Stressgen might be able to take it to market without a partner.

- NK natural killer cells were mentioned as a possible mechanism to explain the action of HspE7 across multiple sub-types of Human Papilloma Virus. Stress proteins have long been known to stimulate NK cells. HspE7 stimulates the CD8 T cells (killer T cells) as well.

The press release:
newswire.ca

Heat.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News